Stock Report

All about this stock under one free report Last Updated: 30-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

IOL Chemicals Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: IOLCP | BSE: 524164

₹207.08

up-down-arrow ₹5.60 (2.78%)

As on 30-Sep-2026IST

Market cap

info icon

₹6,082 Cr

Revenue (TTM)

info icon

₹2,524 Cr

P/E Ratio

info icon

36.2

P/B Ratio

info icon

3.3

Div. Yield

info icon

0.1 %

Edit peer-selector-edit
IOL Chemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 6,082 36,846 27,447 16,931 14,368
Revenue (₹ Cr)
 2,524 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 168.11 1,018.97 497.77 603.02 270.18
Net Margin (%)
 6.60 10.47 20.72 22.63 23.29
RoE (%)
 9.94 21.30 28.49 19.61 14.45
Price to Earnings
 36.18 36.43 55.14 28.08 52.18
Price-To-Book
 3.26 7.04 13.58 4.86 6.93

Income Statement (₹ Cr)

IOL Chemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
2,523.63 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
2,545.82 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
2,213.31 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
310.32 1,943.92 762.90 836.69 388.38
Depreciation arrow
81.80 425.10 98.11 78.88 74.78
EBIT arrow
228.52 1,518.82 664.79 757.81 313.60
Interest arrow
13.96 148.45 26.33 5.43 0.26
Other Income arrow
22.19 47.39 30.80 73.83 51.50
Exceptional Items arrow
-11.21 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
225.54 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
57.43 370.94 171.48 197.53 91.39
Profit after Tax arrow
168.11 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

IOL Chemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
1,798.55 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
0.00 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
98.22 723.57 345.47 142.73 50.51
Current Liabilities arrow
690.18 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
2,630.26 9,514.48 2,930.14 4,157.10 2,231.79

Assets (₹ Cr)

IOL Chemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
1,291.11 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
1,227.63 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
2,630.26 9,514.48 2,930.14 4,157.10 2,231.79
Total Debt* arrow
132.00 1,204.08 196.61 0.00 0.00
Net Current Assets arrow
537.45 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
5.66 258.92 13.18 4.82 3.76

Cashflow (₹ Cr)

IOL Chemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
214.32 943.55 346.68 565.41 266.88
Cash Flow from Investing Activities arrow
-198.11 -1,193.06 -423.73 -570.15 -142.72
Cash from Financing Activities arrow
-29.03 343.43 20.98 -64.34 -112.88
Net Cash Inflow / Outflow arrow
-12.82 93.92 -56.08 -69.08 11.28

Ratios

Profitability Ratios

 IOL Chemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
10.65 25.25 27.50 24.61 18.04
ROE (%) arrow
9.94 21.30 28.49 19.61 14.45
ROA (%) arrow
6.77 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
9.06 15.68 28.03 29.25 28.29
Net Margin (%) arrow
6.60 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 IOL Chemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
18.56 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
65.13 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
60.06 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
-33.09 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
6.57 11.36 22.95 18.43 11.27

Valuation Ratios

 IOL Chemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
34.46 35.68 55.14 27.19 51.72
Price / Book Value arrow
3.26 7.04 13.58 4.86 6.93
Dividend Yield (%) arrow
0.10 0.19 0.16 0.36 0.55
EV/EBITDA arrow
19.37 19.50 35.77 19.30 35.92
Market Cap (₹ Cr) arrow
2,135.62 30,257.56 15,412.11 11,956.86 10,627.92

Solvency Ratios

 IOL Chemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.00 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
0.07 0.16 -- -- --
Current Ratio arrow
1.78 1.43 2.09 5.21 7.39
Quick Ratio arrow
1.24 0.82 1.37 3.85 5.46
Interest Coverage arrow
17.16 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 IOL Chemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
23.90 26.46 22.82 41.42 41.52
Asset Turnover arrow
1.02 1.09 0.93 0.70 0.52
Receivable days arrow
87.89 88.68 77.32 144.58 169.86
Inventory Days arrow
57.58 84.11 80.83 96.67 97.92
Payable days arrow
111.69 176.65 125.94 135.45 159.68
Cash Conversion Cycle arrow
33.78 -3.86 32.22 105.80 108.11
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...